Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.45 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709483 | 0.90 | ESR1 (0.50) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3655152 | 0.81 | ESR1 (0.50) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3844220 | 0.80 | ESR1 (0.57) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL9516545 | 0.78 | MIF (0.45) | ESR1CYP19A1CYP11B2EBPSIGMAR1 | |
| SCHEMBL3653309 | 0.77 | ESR1 (0.54) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3652965 | 0.76 | MAOA (0.47) | ESR1 | |
| SCHEMBL3847255 | 0.75 | ESR1 (0.52) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3709839 | 0.73 | ESR1 (0.48) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3657155 | 0.73 | ESR1 (0.70) | ESR1PTGS1PTGS2CYP19A1CYP11B2 | |
| SCHEMBL3844042 | 0.72 | ESR1 (0.65) | ESR1CYP19A1CYP11B2CYP11B1EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | claimed |
| EP-2200962-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009047343-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-16 | — | — | WO | disclosed |
| EP-2048126-A1 | Benzocycloheptane derivatives as selectively active oestrogens | Bayer Schering Pharma AG (DE) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099250-A1 | BENZOCYCLOHEPTENE DERIVATIVES AS ESTROGENS HAVING SELECTIVE ACTIVITY | CYP19A1, HSD17B11, CYP21A2 | ESR1 4/4885PTGS1 991/4885PTGS2 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.